This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Align Tech (ALGN) and Bausch + Lomb Corporation (BLCO)

Tipranks - Tipranks - Fri May 1, 4:12AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC), Align Tech (ALGN) and Bausch + Lomb Corporation (BLCO).

Claim 55% Off TipRanks

Teladoc (TDOC)

In a report released today, Peter Warendorf from Barclays maintained a Hold rating on Teladoc, with a price target of $7.00. The company’s shares closed last Wednesday at $5.95.

According to TipRanks.com, Warendorf is a 1-star analyst with an average return of -5.7% and a 58.8% success rate. Warendorf covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Healthequity, and Talkspace. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $7.25 average price target, a 21.0% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Align Tech (ALGN)

Barclays analyst Glen Santangelo maintained a Buy rating on Align Tech today and set a price target of $200.00. The company’s shares closed last Wednesday at $178.40, close to its 52-week low of $157.57.

According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 3.9% and a 51.6% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Amphastar Pharmaceuticals, and Bausch Health Companies. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $202.00 average price target, implying a 13.9% upside from current levels. In a report issued on April 16, Citi also initiated coverage with a Buy rating on the stock with a $240.00 price target.

Bausch + Lomb Corporation (BLCO)

Barclays analyst Matt Miksic maintained a Hold rating on Bausch + Lomb Corporation today and set a price target of $20.00. The company’s shares closed last Wednesday at $15.34.

According to TipRanks.com, Miksic is a 3-star analyst with an average return of 1.7% and a 48.9% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., GE Healthcare Technologies Inc, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch + Lomb Corporation with a $18.73 average price target, implying a 16.6% upside from current levels. In a report released yesterday, Needham also maintained a Hold rating on the stock.

Read More on TDOC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).